Curida Holding AS is an integrated contract development and manufacturing organization (CDMO) headquartered in Oslo, Norway, founded in 2015. It offers contract development and GMP manufacturing solutions for small-molecule pharmaceuticals and biologics, focusing on aseptic and non-aseptic liquid manufacturing and specializing in blow-fill-seal (BFS) and nasal spray technologies. For biologics, Curida provides upstream and downstream processing of monoclonal antibodies for in‑vitro diagnostics. Its customer base ranges from small to medium-sized pharmaceutical and biotech companies, serving European clients globally. The company plans to accelerate expansion and enhance facility capabilities following a new investment to grow its industry position. Recent corporate changes include Signet joining the board, Ole J. Dahlberg appointed Chairman, and Anders Larsson named CEO effective May 1, 2024.

Total raised

$23M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024